CCCC
C4 Therapeutics Inc.
$2.61
+$0.15(+6.10%)
53
Overall
60
Value
58
Tech
42
Quality
Market Cap
$224.90M
Volume
1.60M
52W Range
$1.09 - $6.52
Target Price
$11.50
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | $45.8M | $31.1M | $20.8M | $35.6M | ||
| Total Revenue | -- | $45.8M | $31.1M | $20.8M | $35.6M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | $45.8M | $31.1M | $20.8M | $35.6M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $93.6M | $127.9M | $160.6M | $159.8M | $155.2M | ||
| Research & Development | $78.4M | $94.7M | $117.8M | $117.7M | $110.6M | ||
| Research Expense | $78.4M | $94.7M | $117.8M | $117.7M | $110.6M | ||
| Selling, General & Administrative | $15.2M | $33.3M | $42.8M | $42.1M | $42.1M | ||
| General & Administrative Expenses | $15.2M | $33.3M | $42.8M | $42.1M | $42.1M | ||
| Salaries & Wages | -- | -- | -- | $27.2M | $29.7M | ||
| Depreciation & Amortization | $1.6M | $1.5M | $1.7M | $1.6M | $1.5M | ||
| Depreciation & Amortization | $1.6M | $1.5M | $1.7M | $1.6M | $1.5M | ||
| Other Operating Expenses | -- | $3.5M | $10.6M | $159.8M | $155.2M | ||
| OPERATING INCOME | |||||||
| Operating income | $-60.4M | $-82.1M | $-129.5M | $-139.0M | $-119.6M | ||
| EBITDA | $-64.1M | $-80.3M | $-124.3M | $-121.8M | $-97.0M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $1.2M | $2.1M | $2.2M | $1.0M | -- | ||
| Intinc | $393.0K | $387.0K | $3.6M | $9.8M | $14.4M | ||
| Net Non-Operating Interest Income/Expense | $393.0K | $387.0K | $-1.4M | $9.8M | $14.4M | ||
| Other Income/Expense | $-26.3M | $2.9M | $5.6M | $-3.4M | $-180.0K | ||
| Other Special Charges | $26.3M | $-2.1M | $-2.2M | $-600.0K | $14.4M | ||
| SPECIAL ITEMS | |||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $2.4M | ||
| Special Income Charges | -- | -- | -- | -- | $-2.4M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-65.7M | $-81.7M | $-126.0M | $-130.2M | $-105.2M | ||
| Pre-Tax Income | $-67.0M | $-84.7M | $-128.2M | $-131.2M | $-105.2M | ||
| INCOME TAX | |||||||
| Tax Provision | $-626.0K | -- | -- | $1.3M | $100.0K | ||
| NET INCOME | |||||||
| Net Income | $-66.3M | $-83.9M | $-128.2M | $-132.5M | $-105.3M | ||
| Net Income (Continuing Operations) | $-66.3M | $-83.9M | $-128.2M | $-132.5M | $-105.3M | ||
| Net Income (Discontinued Operations) | $-66.3M | $-83.9M | $-128.2M | $-132.5M | $-105.3M | ||
| Net Income (Common Stockholders) | $-66.3M | $-83.9M | $-128.2M | $-132.5M | $-105.3M | ||
| Normalized Income | -- | -- | -- | -- | $-101.7M | ||
| TOTALS | |||||||
| Total Expenses | $93.6M | $127.9M | $160.6M | $159.8M | $155.2M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $11.4M | $46.0M | $48.9M | $49.6M | $69.4M | ||
| Average Shares Outstanding (Diluted) | $11.4M | -- | $48.9M | $49.6M | $69.4M | ||
| Shares Outstanding | $43.1M | $48.7M | $49.1M | $68.6M | $71.0M | ||
| Basic EPS | $-5.83 | $-1.82 | $-2.62 | $-2.67 | $-1.52 | ||
| Basic EPS (Continuing Operations) | $-5.83 | $-1.82 | $-2.62 | $-2.67 | $-1.52 | ||
| Diluted EPS | $-5.83 | $-1.82 | $-2.62 | $-2.67 | $-1.52 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.62 | $-2.67 | $-1.52 | ||
| OTHER METRICS | |||||||
| Other Gand A | $15.2M | $33.3M | $42.8M | $42.1M | $42.1M | ||
| Restruct | -- | -- | -- | -- | $2.4M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CCCC | $2.61 | +6.1% | 1.60M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |